Search Results - "De La Fuente, Macarena"

Ivosidenib in Isocitrate Dehydrogenase 1 - Mutated Advanced Glioma by Mellinghoff, Ingo K, Ellingson, Benjamin M, Touat, Mehdi, Maher, Elizabeth, De La Fuente, Macarena I, Holdhoff, Matthias, Cote, Gregory M, Burris, Howard, Janku, Filip, Young, Robert J, Huang, Raymond, Jiang, Liewen, Choe, Sung, Fan, Bin, Yen, Katharine, Lu, Min, Bowden, Chris, Steelman, Lori, Pandya, Shuchi S, Cloughesy, Timothy F, Wen, Patrick Y

“…Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor…”
Get full text

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial by Mellinghoff, Ingo K, Penas-Prado, Marta, Peters, Katherine B, Burris, 3rd, Howard A, Maher, Elizabeth A, Janku, Filip, Cote, Gregory M, de la Fuente, Macarena I, Clarke, Jennifer L, Ellingson, Benjamin M, Chun, Saewon, Young, Robert J, Liu, Hua, Choe, Sung, Lu, Min, Le, Kha, Hassan, Islam, Steelman, Lori, Pandya, Shuchi S, Cloughesy, Timothy F, Wen, Patrick Y

“…Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is…”
Get full text

Resection versus biopsy in the treatment of multifocal glioblastoma: a weighted survival analysis by Di, Long, Heath, Rainya N., Shah, Ashish H., Sanjurjo, Alexander D., Eichberg, Daniel G., Luther, Evan M., de la Fuente, Macarena I., Komotar, Ricardo J., Ivan, Michael E.

“…Object Diffuse tumor invasion in multifocal/multicentric GBM (mGBM) often foreshadows poor survival outcome. The correlation between extent of resection in…”
Get full text

Bilateral radiation therapy followed by methotrexate‐based chemotherapy for primary vitreoretinal lymphoma by Fuente, Macarena I., Alderuccio, Juan Pablo, Reis, Isildinha M., Omuro, Antonio, Markoe, Arnold, Echegaray, Jose J., Davis, Janet L., Harbour, J. William, Lossos, Izidore S.

“…Primary vitreoretinal lymphoma (PVRL) is a subset of primary CNS lymphoma that presents as isolated ocular disease without brain involvement. Although ocular…”
Get full text

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation by Alderuccio, Juan Pablo, Zhao, Wei, Desai, Amrita, Ramdial, Jeremy, Gallastegui, Nicolas, Kimble, Erik, Fuente, Macarena I., Husnain, Muhammad, Rosenblatt, Joseph D., Alencar, Alvaro J., Schatz, Jonathan H., Moskowitz, Craig H., Chapman, Jennifer R., Vega, Francisco, Reis, Isildinha M., Lossos, Izidore S.

“…Between 11 and 37% of extranodal marginal zone lymphoma (EMZL) patients present with disease involvement in multiple mucosal sites (MMS). We analyzed 405 EMZL…”
Get full text

Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging by Bell, Jonathan B, Jin, William, Goryawala, Mohammed Z, Azzam, Gregory A, Abramowitz, Matthew C, Diwanji, Tejan, Ivan, Michael E, Del Pilar Guillermo Prieto Eibl, Maria, de la Fuente, Macarena I, Mellon, Eric A

“…Glioblastoma (GBM) cellularity correlates with whole brain spectroscopic MRI (sMRI) generated relative choline to N-Acetyl-Aspartate ratio (rChoNAA) mapping…”
Get full text

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial by de la Fuente, Macarena I, Colman, Howard, Rosenthal, Mark, Van Tine, Brian A, Levacic, Danijela, Walbert, Tobias, Gan, Hui K, Vieito, Maria, Milhem, Mohammed M, Lipford, Kathryn, Forsyth, Sanjeev, Guichard, Sylvie M, Mikhailov, Yelena, Sedkov, Alexander, Brevard, Julie, Kelly, Patrick F, Mohamed, Hesham, Monga, Varun

“…Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of…”
Get full text

The role of bevacizumab in the treatment of glioblastoma by Diaz, Roberto Jose, Ali, Sheikh, Qadir, Mehreen Gull, De La Fuente, Macarena I., Ivan, Michael E., Komotar, Ricardo J.

“…Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the…”
Get full text

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas by Brastianos, Priscilla K., Twohy, Erin, Geyer, Susan, Gerstner, Elizabeth R., Kaufmann, Timothy J., Tabrizi, Shervin, Kabat, Brian, Thierauf, Julia, Ruff, Michael W., Bota, Daniela A., Reardon, David A., Cohen, Adam L., De La Fuente, Macarena I., Lesser, Glenn J., Campian, Jian, Agarwalla, Pankaj K., Kumthekar, Priya, Mann, Bhupinder, Vora, Shivangi, Knopp, Michael, Iafrate, A. John, Curry, William T., Cahill, Daniel P., Shih, Helen A., Brown, Paul D., Santagata, Sandro, Barker, Fred G., Galanis, Evanthia

“…Genetic analysis has shown the presence of activating BRAF mutations in 94% of papillary craniopharyngiomas. A phase 2 study showed partial response or better…”
Get full text

Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection by Shah, Ashish H., Mahavadi, Anil, Di, Long, Sanjurjo, Alexander, Eichberg, Daniel G., Borowy, Veronica, Figueroa, Javier, Luther, Evan, de la Fuente, Macarena Ines, Semonche, Alexa, Ivan, Michael E., Komotar, Ricardo J.

“…Purpose Extent of resection remains a paramount prognostic factor for long-term outcomes for glioblastoma. As such, supramaximal resection or anatomic…”
Get full text

SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology by Chukwueke, Ugonma N, Vera, Elizabeth, Acquaye, Alvina, Hervey-Jumper, Shawn L, Odia, Yazmin, Klesse, Laura J, Dunbar, Erin, Sharma, Akanksha, Fonkem, Ekokobe, Thomas, Alissa A, Werbowetski-Ogilvie, Tamra E, Camelo-Piragua, Sandra, Gatson, Na Tosha N, de la Fuente, Macarena I, Armstrong, Terri S, Porter, Alyx B, Jackson, Sadhana

“…Abstract Background Neuro-oncology has grown tremendously since 2010, marked by increasing society membership, specialized clinical expertise, and new…”
Get full text

Central nervous system emergencies in haematological malignancies by Fuente, Macarena I., Alderuccio, Juan Pablo, Lossos, Izidore S.

“…Summary Neurological emergencies are frequently catastrophic events in the course of haematological malignancies (HM) that, if not promptly recognized and…”
Get full text

Simulated Adaptive Radiotherapy for Shrinking Glioblastoma Resection Cavities on a Hybrid MRI-Linear Accelerator by Guevara, Beatriz, Cullison, Kaylie, Maziero, Danilo, Azzam, Gregory A, De La Fuente, Macarena I, Brown, Karen, Valderrama, Alessandro, Meshman, Jessica, Breto, Adrian, Ford, John Chetley, Mellon, Eric A

“…During radiation therapy (RT) of glioblastoma, daily MRI with combination MRI-linear accelerator (MRI-Linac) systems has demonstrated significant anatomic…”
Get full text

A Deep Learning Approach for Automatic Segmentation during Daily MRI-Linac Radiotherapy of Glioblastoma by Breto, Adrian L, Cullison, Kaylie, Zacharaki, Evangelia I, Wallaengen, Veronica, Maziero, Danilo, Jones, Kolton, Valderrama, Alessandro, de la Fuente, Macarena I, Meshman, Jessica, Azzam, Gregory A, Ford, John C, Stoyanova, Radka, Mellon, Eric A

“…Glioblastoma changes during chemoradiotherapy are inferred from high-field MRI before and after treatment but are rarely investigated during radiotherapy. The…”
Get full text

Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences by de la Fuente, Macarena I., Haggiagi, Aya, Moul, Adrienne, Young, Robert J., Sidani, Charif, Markoe, Arnold, Vega, Francisco, DeAngelis, Lisa M., Lossos, Izidore S.

“…Dural lymphoma (DL) is a rare type of primary CNS lymphoma arising from the dura mater. The optimal treatment is uncertain. A retrospective review was…”
Get full text

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1 -mutant glioblastoma: a case report from a Phase I study by Tejera, Dalissa, Kushnirsky, Marina, Gultekin, Sakir H, Lu, Min, Steelman, Lori, de la Fuente, Macarena I

“…Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year…”
Get full text

Targeting IDH1/IDH2 mutations in gliomas by de la Fuente, Macarena I.

“…Somatic point mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) are a defining feature of the majority of WHO grade 2-3 diffuse glioma and the…”
Get full text

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma by Mellinghoff, Ingo K., van den Bent, Martin J., Blumenthal, Deborah T., Touat, Mehdi, Peters, Katherine B., Clarke, Jennifer, Mendez, Joe, Yust-Katz, Shlomit, Welsh, Liam, Mason, Warren P., Ducray, François, Umemura, Yoshie, Nabors, Burt, Holdhoff, Matthias, Hottinger, Andreas F., Arakawa, Yoshiki, Sepulveda, Juan M., Wick, Wolfgang, Soffietti, Riccardo, Perry, James R., Giglio, Pierre, de la Fuente, Macarena, Maher, Elizabeth A., Schoenfeld, Steven, Zhao, Dan, Pandya, Shuchi S., Steelman, Lori, Hassan, Islam, Wen, Patrick Y., Cloughesy, Timothy F.

“…Mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. The IDH inhibitor vorasidenib improved progression-free survival as compared with…”
Get full text

Adult-type Diffuse Gliomas by de la Fuente, Macarena I

“…This article highlights key aspects of the diagnosis and management of adult-type diffuse gliomas, including glioblastomas and IDH-mutant gliomas relevant to…”
Get full text

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution by Alderuccio, Juan Pablo, Zhao, Wei, Desai, Amrita, Gallastegui, Nicolas, Ramdial, Jeremy, Kimble, Erik, de la Fuente, Macarena I, Rosenblatt, Joseph D, Chapman, Jennifer R, Vega, Francisco, Reis, Isildinha M, Lossos, Izidore S

“…Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large…”
Get full text